Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin

All of RECERCAT

To access the full text documents, please follow this link: http://hdl.handle.net/2445/133877

Title:	Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin
Author:	Sicras Mainar, Antoni; Rejas, Javier; Pérez-Paramo, Maria; Sánchez-Alvarez, Luis; Navarro-Artieda, Ruth; Darbà, Josep
Other authors:	Universitat de Barcelona
Abstract:	Background: Discrepancies are seen between arguments in favor of and against prescribing generic versus brand-name drugs. Objective: To provide real-world evidence on treatment persistence, economic and clinical outcomes of pregabalin, generic versus brand-name (Lyrica®, Pfizer), routinely used to treat neuropathic pain (NP) or generalized anxiety disorder (GAD). Methods: Electronic medical records from subjects' first starting treatment with pregabalin between January-2015 and June-2016 were analyzed. Persistence, resources utilization, and costs were assessed, along with remitter and responder rates. (...)
Subject(s):	-Medicaments -Medicaments genèrics -Anàlisi cost-benefici -Neuropsicofarmacologia -Tractament del dolor -Ansietat -Drugs -Generic drugs -Cost effectiveness -Neuropsychopharmacology -Pain treatment -Anxiety
Rights:	(c) Informa Healthcare, 2019 info:eu-repo/semantics/embargoedAccess
Document type:	Article Article - Accepted version
Published by:	Informa Healthcare
Share: